Rivaroxaban for Treatment of Left Ventricular Thrombus: A Case Report

25 June 2021: Articles

Unusual clinical course, Unusual or unexpected effect of treatment, Educational Purpose (only if useful for a systematic review or synthesis)

Juhaina Salim Al-Maqbali ^A , Maitha Al-Sibani ^B , Nasiba Al-Maqrashi ^A , Abdullah M. Al Alawi ^A* , Hatim Al Lawati ^A

DOI: 10.12659/AJCR.932140

Am J Case Rep 2021; 22:e932140

Table 1. Laboratory test results on the day of presentation.

Range	Patient’s result	Range
HB	15.3 g/dl	11.5–15.5
Platelets	209×10/L	150–450
WCC	7.0×10/L	2.2–10.0
INR	1.25	0.90–1.10
APTT	26.8 sec	24.1–35.1
PT	13.4 sec	9.8–12.0
Thrombin time	19.9 sec	12.8–17.6
Fibrinogen	4.7 g/L	1.7–3.6
Anion gap	14 mmol/L	5–13
Bicarbonate	23 mmol/L	22–29
Chloride	97 mmol/L	98–107
Creatinine	90 Umol/L	59–104
Potassium	4.1 mmol/L	3.5–5.1
Sodium	134 mmol/L	135–145
Urea	5.8 mmol/L	2.8–8.1
Alanine aminotransferase	114 U/L	0–41
Albumin	31 g/L	35–52
Alkaline phosphate	159 U/L	40–129
Aspartate aminotransferase	212 U/L	0–40
Bilirubin, total	34 U/L	0–17
Portion, total	63 U/L	66–87
Troponin	108 ng/L